This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bristol-Myers Squibb Company
Drug Names(s): Mevalotin, Pravastatin Sodium
Description: Pravachol inhibits HMG-CoA reductase, an enzyme required for the synthesis of cholesterol.
Deal Structure: Bristol-Myers licensed a patent covering pravastatin from Sankyo Company, Ltd. (Sankyo) of Japan, with the agreement expiring as exclusivity expires on a market-by-market basis. Exclusivity in the U.S. under the patent (including pediatric extension) expired in April 2006. Under the terms of the license, Bristol-Myers may market and sell pravastatin throughout the world, excluding Japan, Korea, Taiwan and Thailand (markets in which Sankyo retains exclusive patent rights). Sankyo also copromotes and comarkets pravastatin in certain European and Latin American countries.
Partners: Daiichi Sankyo Co., Ltd.
Pink Sheet Teva’s Pravastatin ANDA Approved
Additional information available to subscribers only: